Startup Profiles: Upstream Bio Gets Another $200M, Kate Therapeutics Debuts with $51M

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Versant-Backed Nexo Gets $60M to Pursue Tough Cancer Targets
Westlake Village Raises $450M for Biotech Startups in LA and Beyond
Abdera Gets $142M To Make Potent, Safe, Radioantibodies for Cancer
Belharra Gets $130M from Versant, Genentech For Chemoproteomic Discovery